Drugs / COVID-HIG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05142306 | Dec 2021 → Mar 2022 | COVID-19 | Emergent BioSolutions | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-04-02 | Emergent BioSolutions | Results Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19 emergentbiosolutions.com ↗
There were no serious safety concerns identified. |
All press releases naming this drug 3 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVID-HIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05142306 ↗ |
| Action | Inhibit | “containing antibodies (including neutralizing antibodies) to SARS-CoV-2.” NCT05142306 ↗ |
| Modality | Protein / enzyme biologic | “purified immunoglobulin G (IgG) liquid preparation” NCT05142306 ↗ |
| Route | Intramuscular | “receive an 8.5mL dose of COVID-HIG by IM injections.” NCT05142306 ↗ |